股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和譽開曼有限责任公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02256 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總 ...

Group 1 - The Hang Seng Index fell by 1.07%, down 287 points, closing at 26,669 points, while the Hang Seng Tech Index decreased by 1.09% [1] - Gold stocks continued their recent upward trend, with New York gold prices surpassing $4,000; Zijin Mining International rose by 5.98%, Chifeng Jilong Gold increased by over 14%, and Shandong Gold gained 7.56% [1] Group 2 - Xinjiang Xin Mining (03833) surged over 19%, with its stock price nearly doubling after returning to A-shares, owning four nickel-copper mines [2] - Jinli Permanent Magnet (06680) rose over 6%, with institutions optimistic about the rare earth sector's valuation and performance [2] - Shanghai Electric (02727) increased by over 4% following a key breakthrough in the compact fusion energy project BEST in Hefei, Anhui [2] - Heyu-B (02256) climbed over 8% to reach a historical high, with the upcoming launch of Pimiatin expected to provide ongoing sales revenue [2] Group 3 - Yiming Anke-B (01541) rose over 7% after submitting an application for the Phase III clinical trial of IMM2510 [3] Group 4 - Botai Carlink (02889) increased over 19%, collaborating with SenseTime to promote AI applications in smart connected vehicles [4] - Changfeng Pharmaceutical (02652) debuted with a high opening of 218.64%, later rising over 180%, focusing on inhalation technology and inhalation drugs [4] Group 5 - China Cosco Shipping Energy Transportation (01138) fell over 3.7%, as OPEC+ production increases were significantly lower than previously reported, raising market concerns about oil transportation demand [5] Group 6 - Cryptocurrency-related stocks experienced significant declines, with Boya Interactive (00434) dropping over 8% as Bitcoin's plunge affected the crypto market [6]

Group 1: Hong Kong Stock Market Highlights - Jinli Permanent Magnet (06680) rose over 5%, with institutions optimistic about valuation and performance in the rare earth sector [1] - Heyu-B (02256) increased by more than 7%, as the upcoming launch of Pimiatin is expected to provide continuous sales revenue [1] - Sa Sa International (00178) saw a rise of over 6%, with a 8.4% year-on-year increase in revenue for the second fiscal quarter [1] - Gold stocks continued their recent upward trend, with Chifeng Jilong Gold Mining (06693) up over 14% and Zijin Mining International (02259) up over 7% [1] - Xinjiang Xin Mining (03833) surged over 17%, with the company announcing a near doubling of stock price after its return to A-shares [1] Group 2: U.S. Stock Market Highlights - AMD (AMD.US) rose 3.83% after announcing a 6 GW computing power agreement with OpenAI for future AI infrastructure [3] - Trilogy Metals (TMQ.US) skyrocketed 211% following the U.S. government's announcement to acquire a 10% stake in the company [3] - AppLovin (APP.US) increased by 7.64%, amid reports of an SEC investigation regarding its advertising practices [3] - Ford Motor Company (F.US) fell 6.14% due to a significant fire at a key production facility, expected to halt operations until next year [4] - Soluna Holdings (SLNH.US) surged 12.78%, reporting an increase in mining capacity from 526 PH/s in August to 658 PH/s in September [4]

（文章来源：每日经济新闻） 每经AI快讯，10月8日，港股和誉-B(02256.HK)早盘涨超8%，截至发稿，涨8.2%，报19.4港元，成交额 5846.51万港元。 ...

Core Viewpoint - He Yu-B (02256) experienced a significant increase of over 8% in early trading, reaching a price of 19.4 HKD, with a trading volume of 58.4651 million HKD. The report from China Merchants Securities International highlights the potential of the drug pitmiritinib, developed by He Yu, as the most effective CSF-1R small molecule globally, which is set to launch in both China and the U.S., promising ongoing sales revenue for the company. The firm anticipates that Merck has high expectations for this molecule, projecting peak sales revenue close to 1.5 billion USD globally. Citigroup previously noted that the company's valuation reflects only the value of its two late-stage candidates, pitmiritinib and ipatacitinib, while the market has yet to fully recognize the high licensing potential of its differentiated innovative drugs [1][1][1]. Group 1 - He Yu-B's stock rose by 8.2%, reaching 19.4 HKD with a trading volume of 58.4651 million HKD [1] - The drug pitmiritinib is expected to launch in both China and the U.S., providing continuous sales revenue for the company [1] - Merck has high expectations for pitmiritinib, with projected peak sales revenue nearing 1.5 billion USD globally [1] Group 2 - Citigroup indicated that the current valuation of He Yu-B only reflects the value of its two late-stage candidates, pitmiritinib and ipatacitinib [1] - The market has not yet fully recognized the high licensing potential of He Yu-B's differentiated innovative drugs [1]

Core Viewpoint - The stock of He Yu-B (02256) has seen a significant increase of over 8%, currently trading at 19.4 HKD, driven by positive market sentiment regarding its drug development [1] Group 1: Company Performance - He Yu-B's drug, Pimitinib, is recognized as the most effective CSF-1R small molecule globally and is set to launch in both China and the U.S., which will provide the company with ongoing sales revenue sharing [1] - The stock's trading volume reached 58.4651 million HKD, indicating strong investor interest [1] Group 2: Market Expectations - According to a report from China Merchants Securities International, Merck has high expectations for Pimitinib, with potential peak sales revenue approaching 1.5 billion USD globally [1] - Citigroup previously noted that the company's valuation reflects only the value of its two late-stage drug candidates, Pimitinib and Ipatasertib, suggesting that the market has not fully recognized the high licensing potential of its differentiated innovative drugs [1]

Core Viewpoint - The report from China Merchants Securities Hong Kong initiates coverage on HeYue-B (02256) with a "Buy" rating, estimating a fair equity value of HKD 21 billion and a target price of HKD 32.5 for the next 12 months, highlighting the company's long-term growth potential and efficient small molecule development capabilities [1] Group 1: Product Development and Market Potential - HeYue's developed drug, Pimitinib, is expected to be launched in both China and the U.S., providing continuous sales revenue through profit-sharing [1] - The company is actively targeting two significant gene families, FGFR and KRAS, with FGFR4 as a late-stage clinical asset poised to become a new targeted small molecule in liver cancer [1] - The global sales peak for Pimitinib is projected to reach USD 1.5 billion, providing sustained cash flow for HeYue [1] Group 2: Clinical Advancements and Pipeline - HeYue has demonstrated the best efficacy globally for TGCT in the development of CSF-1R inhibitors, with superior safety and response rates compared to similar molecules [1] - The company has received over USD 150 million in cash from its collaboration with Merck, including milestone payments and sales revenue sharing, marking a significant achievement for a Chinese biotech firm in global commercialization [1] - HeYue has a robust pipeline with 22 candidate drugs, including 12 in clinical stages and 10 in preclinical stages, showcasing its leading recognition of frontier targets and clinical development capabilities [3] Group 3: Focus on FGFR and RAS Targets - The company has been deeply engaged in the FGFR target area for ten years, focusing on selective FGFR4 inhibitors and FGFR2/3 inhibitors, addressing unmet needs in liver and gastric cancers [2] - The selective FGFR4 inhibitor, Ipagotinib, is currently in critical Phase III clinical trials, potentially becoming the first approved selective inhibitor targeting FGFR4 globally [2] - HeYue is also developing early-stage molecules targeting G12D and pan-RAS, which will enhance its offerings in precision oncology [2]

Core Viewpoint - The report from China Merchants Securities Hong Kong initiates coverage on HeYue-B (02256) with a "Buy" rating, estimating a fair equity value of HKD 21 billion and a target price of HKD 32.5 for the next 12 months, highlighting the company's long-term growth potential and efficient small molecule development capabilities [1] Group 1: Product Development and Market Potential - HeYue's developed drug, Pimitinib, is positioned as the most effective CSF-1R small molecule globally and is set to launch in both China and the U.S., promising ongoing sales revenue for the company [1] - The company is actively targeting two significant families of important targets, FGFR and KRAS, with FGFR4 as a late-stage clinical asset expected to become a new targeted small molecule in the liver cancer field [1] - The global sales peak for Pimitinib is projected to reach USD 1.5 billion, providing a continuous cash flow for HeYue, with the drug being a key asset in Merck's pipeline [1] Group 2: Clinical Advancements and Pipeline - HeYue has demonstrated the best efficacy globally for TGCT in the development of CSF-1R inhibitors, with safety and response rates surpassing similar molecules [1] - The company has established a robust pipeline with 22 candidate drugs, including 12 in clinical stages and 10 in preclinical stages, showcasing its leading recognition of frontier targets and developing clinical capabilities [3] - The selective FGFR4 inhibitor, currently in pivotal Phase III trials, targets advanced liver cancer patients with FGF19 overexpression, marking a potential first in the global market if successful [2] Group 3: Strategic Focus on Targeted Therapies - The company has been focusing on the FGFR target for a decade, with a deep layout in selective FGFR4 inhibitors and FGFR2/3 inhibitors, addressing unmet needs in liver and gastric cancers [2] - The ongoing research on RAS targets, including early-stage molecules for G12D and pan-RAS, is expected to enhance the company's offerings in precision oncology [2] - The development of next-generation FGFR inhibitors and oral PD-L1 small molecules is anticipated to exceed market expectations through better data disclosure and potential business development transactions [3]

智通财经APP讯，和誉-B(02256)发布公告，本公司于2025年9月29日根据首次公开发售后购股权计划授 出 634.35万份购股权(购股权)予本公司的三名董事(董事)及若干雇员(合称"购股权承授人")，惟须待购股 权承授人接纳方可作实。 本公司于2025年9月29日根据2019年股权激励计划授出460.64万份受限制股份单位(受限制股份单位)予本 公司的若干雇员(受限制股份单位承授人)，惟须待受限制股份单位承授人接纳方可作实。 ...

格隆汇9月29日丨和誉-B(02256.HK)公告，公司于2025年9月29日根据首次公开发售后购股权计划授出 6,343,508份购股权予公司的三名董事及若干雇员，惟须待购股权承授人接纳方可作实。公司于2025年9 月29日根据2019年股权激励计划授出4,606,372份受限制股份单位予公司的若干雇员，惟须待受限制股份 单位承授人接纳方可作实。 ...